GlassScriptPhysician profile
Jamie Wallace
NPI 1104608595
$2,286.33
in general payments reported to CMS, 2019-2025
23 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $705 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $307.17 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $157.60 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alk-Abello, INC | $142.80 | 2025 | Grastek, Odactra, Ragwitek |
| Lilly USA, LLC | $142.72 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $142.48 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $129.50 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $122.45 | 2024-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $110.61 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $84.35 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $81.86 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.22 | 2024-2025 | Jardiance |
| Pfizer INC. | $70.21 | 2024-2025 | |
| Insulet Corporation | $50.99 | 2024-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.72 | 2024-2025 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.03 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $36.91 | 2025 | |
| Lundbeck LLC | $34.14 | 2025 | Rexulti |
| Corium, LLC | $29.27 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $26.50 | 2025 | Capvaxive |
| Sumitomo Pharma America, INC. | $25.27 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $23.46 | 2024 | Auvelity |
| Ibsa Pharma INC. | $18.71 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.